• Correlate posts significant increase in Q2 revenue from $1,584 in 2021 to $236,690 in 2022
• Customer deposits have also increased, from $0 during the same period in 2021 to $1,114,154 in Q2 2022, while operating expenses have grown from $4,937 to $1,444,794
• Correlate has attributed the growth to the increased emphasis on commercialization, a shift from previous quarters that focused on product development
• The company hopes to maintain the current trajectory in performance, mainly banking on helping its commercial customers increase their NOI while also maturing its aggressive acquisition strategy

Correlate Infrastructure Partners (OTCQB: CIPI), earlier released its results for the 2021 financial year, where CEO Todd Michaels expressed his optimism for 2022, mainly banking on the learnings from 2021 and building on the company’s focus toward more revenue-generating initiatives. “In 2022, we anticipate revenues to increase with the expansion of operations, sales channels, and repeat business from our 2021 portfolio of national accounts,” Mr. Michaels noted. “The post-pandemic U.S. commercial and industrial market has approximately 6.8 million facilities capable for our solution to increase building owner net income. With only about 3% of those facilities currently being addressed, demand is very high. We couldn’t be more confident and excited about our position for tremendous growth,” he added (https://ibn.fm/P1RJ2). Correlate has since released its financial results for the second quarter (“Q2”) ended June 30, 2022, and the year to date ended June 30, 2022, noting a significant increase in revenue from $1,584 for the same period in 2021 to $236,690. In addition, customer deposits for Q2 totaled $1,114,154, up from $0 for the same period in 2021 (https://ibn.fm/GkrJX). Correlate attributed this significant growth in performance to the shift in the business to commercialization, compared to previous quarters where there was significant product development. In addition, customer deposits accounted for approximately 32% of revenue from contracts with three key customers whose projects are under installation. Operating expenses for Correlate saw an increase from $4,937 over the same period in 2021 to $1,444,794 in Q2 2022. This was credited to higher professional fees associated with acquisition activities and higher wage expenses associated with bringing on board new personnel to support growth. Correlate currently has project opportunities valued at $74 million from recent awards at different stages, including projects that have been awarded agreements in development and contracts that have been executed under installation. In addition, it remains committed to growing as a full-service energy optimization service provider, and its management is confident that it will maintain its current performance trajectory. “By helping commercial customers increase net operating income (“NOI”) through our clean energy solutions, the benefits of our innovative full-service platform becomes a more integral part of real estate asset management,” noted Mr. Michaels. “We are also actively maturing our aggressive acquisition strategy by identifying targets that complement our technology stack or provide fulfillment capabilities in key regions,” he added. So far, Correlate has achieved its revenue forecasts for the 2022 financial year. It looks to maintain its current performance by further focusing on commercialization and growing its customer numbers, ultimately growing its revenue and creating value for its shareholders. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income:  www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals:  www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• New York-based institutional fund manager The Lind Partners has reached an investment agreement with mobile device technology innovator FingerMotion Inc. to provide FingerMotion $4 million that will advance its initiatives
• FingerMotion is focused on varied initiatives for serving China’s massive mobile device user market, its top priority being the rollout of an AppleCare-similar device protection plan the company expects to be popular with users
• Company CEO Martin Shen has stated the protection plan service has the highest potential to yield returns on capital investment in the shortest amount of time
• China has more than 450 million 5G mobile phone users and their need to upgrade their devices and services holds the key to FingerMotion’s strategy

FingerMotion (NASDAQ: FNGR), a U.S.-based company currently focused on serving the huge market for mobile phone-related technologies on the Asian continent, has received an agreement for the infusion of new capital in its enterprise and is preparing to utilize it to drive quick revenue growth. The funding agreement with New York-based institutional fund manager The Lind Partners to obtain gross proceeds of $4 million through an investment by the Lind Global Fund II, LP will help FingerMotion advance various growth strategies in return for a $4.8 million senior convertible note (which includes a 20 percent coupon) and a common stock purchase warrant for buying up to nearly 3.5 million shares of common stock of the company at a select price. “The proceeds from this Investment will be primarily allocated across multiple high-margin and high-growth opportunity initiatives currently underway. In particular, the Company’s highest priority initiative is the full-scale nationwide rollout of its mobile device protection business in China,” CEO Martin Shen stated in the company’s announcement (https://ibn.fm/IsHYa). “This vertical is expected to yield the highest return on capital investment in the shortest amount of time, both strengthening our balance sheet and enabling us to experience transformational revenue growth over the next 12-24 months.” The device protection solution mirrors Apple’s AppleCare service in the Chinese market, which FingerMotion expects to be received by consumers as an innovative and needed product, and one that will be able to pervade the market thanks to FingerMotion’s success in partnering with telecommunications giants China Unicom and China Mobile to reach a wide base of mobile users. Global Times reported there are now more than 450 million 5G mobile phone users in China — the primary target for device protection as they upgrade their products. The report also states all prefecture-level cities have implemented optical network broadband and that the networks have more than 61 million users (https://ibn.fm/9FsBE). The Lind fund’s investment note will have a 24-month maturity. In addition to the mobile device protection service, FingerMotion has been a significant provider of top-up and SMS services and is developing a big data service for reinsurance providers to help assess consumer risk. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Odyssey Health is a medical company focused on developing unique, life-saving medical products that offer clinical advantages for unmet clinical needs
• Recently, the company reported positive results from Cohort I of its Multi-Day Ascending Dosing (“MAD”) portion of its Phase I clinical trial, coming weeks after the successful completion of Phase I Single Ascending Dosing (“SAD”) clinical trial
• The MAD arm thus far shows that the drug is safe and well tolerated
• Odyssey expects to report additional MAD results as they become available

A few weeks after completing its Phase I Single Ascending Dosing (“SAD”) clinical trial, Odyssey Health (OTC: ODYY) recently announced positive results from Cohort I of its Multi-Day Ascending Dosing (“MAD”) portion for its Phase I clinical trial evaluating the efficacy and safety of PRV-002 (https://ibn.fm/2zS5F), the company’s novel drug candidate for treating concussion. For Odyssey, a medical company focused on creating and commercializing unique, life-improving medical products, concussion – a mild traumatic brain injury (“mTBI”) caused by a jolt, bump, or blow to the head – represented an unmet clinical need. Despite its high prevalence in the U.S., with figures showing that as many as five million concussions occur annually (https://ibn.fm/qV6NY), the condition does not have a Food and Drug Administration (“FDA”)-approved drug. “Odyssey’s primary drug candidate is being developed as the first treatment for concussion,” a white paper posted on the company’s website reads (https://ibn.fm/GCgFp). “The drug candidate, PRV-002, is a novel neurosteroid that easily crosses the blood-brain barrier.” The company completed the GMP synthesis of PRV-002 and all pre-clinical efficacy studies, which showed that the drug candidate “improves behavioral (working memory, motor performance, and anxiety levels) and molecular (inflammation, oxidative stress, and swelling) outcomes following brain trauma through an amplified neuroprotective gene response internal to cells in the brain,” and has now embarked on human trials. As part of the ongoing human study, grouped into SAD and MAD portions, Odyssey is administering PRV-002 to healthy human subjects. The successfully completed SAD arm of the Phase I trial involving three cohorts showed the drug was safe and well tolerated, influencing expectations and confidence that PRV-002 will continue to show safety during the MAD portion of the trial. “We have unanimously approved the start of MAD Cohort I,” commented Dallas Hack, MD, member of the Safety Review Committee, following the completion of Phase I SAD trial (https://ibn.fm/WrJDo). “I am especially excited to see the overall low levels of PRV-002 in the blood supporting the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case, not only can the targeted effects of the drug be more efficacious, the drug will likely have less potential side effects.” And with Odyssey having recently announced positive results from Cohort I of the MAD arm of the study, Odyssey’s Phase I clinical trial appears to be ticking all the expected checkboxes. According to the company, the MAD Cohort I (eight healthy subjects) received one low dose of intranasal PRV-002 for five consecutive days, followed by evaluations that showed the drug was safe and well tolerated. “I am very happy to see these positive safety results when dosing for multiple days. PRV-002 appears to be well-tolerated when given intranasally. If PRV-002 is found to be efficacious for concussed patients in the Phase II/III trials, I believe that intranasal brain-targeting will be the key to its success. So far, the intranasal drug/device combination has functioned nicely and has been well-tolerated in the clinical setting,” said Dr. Jacob VanLandingham, the head of drug development for the PRV-002 concussion treatment at Odyssey Health, of the recent positive results. The Phase I MAD clinical trial will involve 16 healthy subjects, with the subsequent cohorts receiving a higher dose than Cohort I. The company expects to report additional MAD results as they become available. For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

The NECANN Conference has evolved into the largest conference on the East Coast, attracting cannabis cultivators, traders, regulators, lawmakers, and enthusiasts, from the East Coast and beyond. The 3rd annual New Jersey Cannabis Convention is being held from September 9-10, 2022, in Atlantic City, New Jersey. This is a well-curated event organized by a highly talented team of professionals with desired expertise and experience. They keep in mind the needs and requirements of the cannabis community and bring together investors, young and veteran cannabis and hemp traders, as well as researchers and lawmakers, all in a common forum. After fighting a tough battle for legalizing both medicinal and recreational cannabis, New Jersey, on February 22nd, 2021, became the fourteenth U.S. state to legalize marijuana completely. Atlantic City has a huge cannabis market waiting to get discovered and tapped by marijuana traders and customers. Also, the city has very limited cannabis dispensary availability to cater to the entire population. The NECANN exhibition will bring the New Jersey cannabis community to the forefront to get discovered by potential investors. The 3rd annual NJ NECANN event will witness an important lineup of speakers and industry veterans. They will share useful insights about the latest industry trends and discuss important issues covering the entire range of topics under the cannabis spectrum. Exhibitors can set up their respective booths to pitch their businesses. The 3rd Annual NJ Cannabis Convention will be a one-of-its-kind experience, to discover more cannabis communities and exchange ideas and information about marijuana businesses. The NECANN team brings in cannabis trade investors and entrepreneurs who are interested in novel and fresh business ideas. Budding entities can leverage the reach of the NECANN platform to gain visibility among potential investors. Established in 2014, NECANN events are one of the largest cannabis conventions offering mammoth networking opportunities. The NECANN events attract Hemp, MMJ, and Cannabis industry professionals, to meet and build critical long-term business ties. The NECANN convention offers a robust platform for local cannabis businesses to showcase their products and services. It allows them to meet the stalwarts of the cannabis community and attract lucrative investments into the developing New Jersey cannabis market. Overall, the event represents a unique opportunity to get in on the ground floor. The NECANN team works tirelessly to cover every aspect of the cannabis industry ranging from inventory, legal issues, packaging, insurance, regulations, security, from testing to cultivation, marketing, and more. To learn more, please visit https://ibn.fm/qwr8m

• Lexaria’s successful HYPER-H21-2 human clinical study, whose results were announced in the first week of September 2021, laid the groundwork for the company’s patented DehydraTECH(TM)-processed CBD NDA
• Chris Bunka, the company’s CEO, referred to the results as “statistically significant,” ultimately kickstarting the IND application process with the FDA
• Lexaria has since received a full written positive response from the FDA on its DehydraTECH-CBD, agreeing to the company’s proposal to pursue the 505(b)(2) NDA regulatory pathway
• As a result of the favorable FDA response, Lexaria expects to remain on track to file its full IND application, 6-9 months sooner than if the FDA had required modifications in Lexaria’s current IND-enabling work plan, and Its management is confident that maintaining the current trajectory could allow the company to achieve $1 billion per year in the hypertension market, even making it one of the most effective registered pharmaceutical treatments for hypertension in the world

In the first week of September 2021, Lexaria Bioscience (NASDAQ: LEXX) announced its most recent results, at the time, from its HYPER-H21-2 human clinical study on the overall effectiveness of its patented DehydraTECH(TM)-processed CBD on blood pressure. The successful study would play an integral role in the company’s eventual New Drug Application (“NDA”), with Chris Bunka, the company’s Chief Executive Officer (“CEO”), terming the results as “statistically significant” (https://ibn.fm/iUObW). The success of multiple human studies investigating DehydraTECH-CBD for hypertension prompted Lexaria to formally announce the process of an Investigational New Drug (“IND”) application filing with the United States Food and Drug Administration (“FDA”) to list DehydraTECH-CBD as a prospective registered pharmaceutical treatment for hypertension. Lexaria has since received a positive full written response from the FDA regarding DehydraTECH-CBD, with the institution confirming that it agreed to Lexaria’s proposal to pursue a 505(b)(2) NDA regulatory pathway that would hasten the process of commercial approval for its product (https://ibn.fm/cBz7R). “We are very pleased to have received comments from the FDA toward opening our IND program, and we will be executing FDA-confirmed IND-enabling work immediately,” noted John Docherty, the President of Lexaria. “We were delighted that our proposals were very well received by the FDA, and the feedback received will be very helpful in compiling and filing our IND application as the new major regulatory step we are focused on moving forward,” he added. The FDA’s communication also noted that additional non-clinical studies would not be required before initiating the DehydraTECH-CBD IND program, particularly given compelling data already presented by the company and others regarding the safety and tolerability of CBD. Lexaria is confident that the approval will go through, especially since the FDA already has a history of approving CBD pharmaceutical treatments. In 2018, this approving body gave the green light to Epidiolex(R), a CBD-based pediatric anti-seizure medication. In the approval, they noted that the approved dosage rate for a child weighing 28kg was 140mg, increasing to 280mg daily for long-term use. Lexaria looks to build on this to push for its DehydraTECH-CBD, hoping to offer a viable solution to millions of people living with hypertension. With the FDA response, Lexaria expects to remain on track to file its complete IND application by late 2022 or early 2023, maintaining the initial targets announced. In addition, given its move to go with the 505(b)(2) pathway as opposed to 505(b)(1), the company looks to shave 6-9 months off of the approval process, bringing its product to the market a lot sooner. When discussing previous results from the hypertension study, Mr. Bunka noted: “If we sustain these results, we could be looking at mega-drug status ($1 billion per year) in the hypertension market.” “Our goal now is to put together a 4-week study, three doses per day, targeting a sustained drop in blood pressure. That could make us one of the most effective registered pharmaceutical treatments for hypertension in the world, with few if any unwanted side effects,” he added. This outlook shows Lexaria’s commitment to creating shareholder value, even as it inches closer to offering a viable solution to people living with hypertension. In addition, its commitment to following due process to receive FDA approval reflects the company’s and management’s clear vision and understanding of what it would take to grow the list of product offerings and offer something unique in the market. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• US traffic-related fatalities touched a 16-year high in 2021, outstripping other major economies across the World
• The US Collision Industry Conference has forecast crash rates to decline by as much as 20% by 2030 on the back of widespread ADAS adoption
• Cepton has pioneered the use of lidar, a key sensor technology, across automotive and smart infrastructure applications. In 2019, the company was the recipient of the single largest ADAS lidar series production award with Koito on the General Motors business
• Cepton has now seen its lidar technology expand far beyond its initial intended use, ranging from revisioning public venues and commercial buildings to transportation infrastructure in Austria with efforts to improve the real–world traffic data from urban landscapes.

US traffic-related fatalities soared to a 16-year high in 2021, touching 42,915 deaths. (https://ibn.fm/RR73k). Astonishingly and despite the evolution of modern automotive safety measures in the United States, the nation suffered over double the number of road fatalities relative to the European Union despite having a population numbering over 100 million less than that of the EU. However, and according to the United States’ Collision Industry Conference (“CIC”), vehicular crash rates could decline by as much as 20 percent by 2030 (https://ibn.fm/grdrY) – largely a result of the ongoing development and adoption of advanced driver assistance systems (“ADAS”). Long-established OEMs and start-ups alike have invested upwards of $106 billion in autonomous driving capabilities dating back to 2010, (https://ibn.fm/NBz1m) with advanced driver assistance systems – which form the foundation on autonomous driving capabilities, an increasingly ubiquitous presence within today’s vehicles through features such as adaptive cruise control, parking assistance, and forward collision warnings. Moreover, ADAS technology is set to evolve in coming years towards the enablement of more intelligent and autonomous driving systems, in turn leading to a host of additional potential benefits – fewer accidents due to human error, a drop in the cost and environmental impact of transport, and safer and more accessible driving, to name just a few. Cepton (NASDAQ: CPTN), a Silicon Valley innovator and pioneer within high-performance lidar solutions, has been a key beneficiary of the increased focus on autonomous vehicles and the development of ADAS, rapidly increasing OEM interest in adding lidar technology to ADAS and autonomous driving systems for higher levels of safety and autonomy. Lidar technology has increasingly gained adepts for its ability to measure the distance of objects in 3D, providing the wherewithal to map the surroundings of an autonomously driven vehicle, quickly and efficiently. Through its significant ADAS lidar series production award with Koito on the General Motors business, Cepton is leading the way in scaling up lidar for mass-market deployments. The scalability allows the company to expand its lidar’s use beyond automotive applications. Ranging from its efforts to resolve traffic congestion in major urban metropolises such as Austria’s mountainous landscapes which encounter different driving scenarios and pedestrian safety. In addition to their collaboration with Lithuania-based system integrator Belam to improve road user and rail passenger safety using obstacle detection at crossings (https://ibn.fm/AWi5V). Cepton’s scalability also reaches as far as incorporating lidar systems in security modalities. Bowler Pons, a specialist in technology-focused enhanced electronic security systems is utilizing Cepton’s anonymous lidar systems for improved detection and categorization, ultimately enabling autonomous alerts while protecting privacy (https://ibn.fm/HW7pV). Dating back to its inception in 2016, Cepton has sought to market the concept of ‘Lidar for Life’, introducing the use of lidar technology in mass-market consumer vehicles as well as the development of smart infrastructure in cities, spaces, and industrial robotics. As a pivotal part of the company’s efforts in promoting lidar technology across different sectors, the company has invested in making lidar a truly scalable and accessible technology – cost efficient, reliable, and easy to integrate into various systems. Dr. Jun Pei, co-founder and CEO of Cepton elaborated on the concept, “[despite being] a very established engineering enterprise, we’re still a start-up in working style with the mentality of each person that the sky is the limit. [Whilst] in the first meeting with an OEM you discuss lidar range and resolution for 10 minutes, [it is then] all about cost. If you are $1 more than the competitor, you are out the door. We captured a huge element in the cost.” (https://ibn.fm/Ajhls). Having played an influential role in a technological revolution which has seen the cost of a single lidar device decline from tens of thousands of dollars several years ago to a few hundred dollars today, it is little wonder that Cepton, amongst dozens of other lidar manufacturers, received GM’s ADAS lidar series production award 2019 to support Ultra Cruise. A pathbreaking program in both the automotive industry and the history of lidar, the award will see Cepton’s lidar as one of the key sensor technologies enabling Ultra Cruise’s safe and autonomous driving capabilities in everyday passenger cars. However, the General Motors engagement is only one reminder of the potential of lidar technology for Dr. Pei, with Cepton envisioning an eventual future where lidar-enabled ADAS technology would be deployed across all vehicles, with the goal of drastically reducing accident rates. “It’s a no-brainer”, said Dr. Pei. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

Life science professionals are invited to attend the 2nd Omnichannel Marketing Strategy Symposium on September 29-30, 2022. Pharmaceutical, biotechnology, and medical device companies are realizing the growing importance of a powerful omnichannel marketing campaign that allows pharma to reach the right people at the right time. This intensifies the need for a substantial marketing plan. Taking into account previous impact and consumer data, marketers can concentrate on promotional spending to optimize their investment. But the vital question is, do marketers in the pharma sphere possess adequate technology and data necessary to make their omnichannel marketing as successful as it could be? The event is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing B2B events. The global event company caters to the dynamic informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries.  DGE’s Omnichannel Marketing Strategy Symposium provides the skills and strategies professionals/companies need for putting together and directing a unique marketing approach, where the marketing plan is tailored to meet the needs and demands of the customers, putting them ahead of the competition. The DGE event offers participants a viable platform for planning and implementing diverse scalable strategies for optimal customer engagement. Top Reasons to Attend

• Learn how to identify and prevent hurdles in your omnichannel marketing journey
• Understand how to channel your regulatory processes to deliver content speedily
• Harness the potential of KOL and discover new strategies in your omnichannel marketing efforts
• Reveal the latest digital and technology on the market to boost your omnichannel marketing campaigns
• Learn the best practices for email marketing and contact lists to stay ahead of competitors

After the opening speech from the chairperson, panel discussions and keynotes from expert speakers will follow. Industry heads will discuss the latest topics requiring immediate attention. Digital marketing experts will throw insights on how to rank your omnichannel marketing strategies against other companies. Understanding how your competitors have developed omnichannel marketing is vital for your journey. Discuss the best practices of marketing and evaluate where your company stands presently in the competitive environment. At this DGE event, learn how other companies perform and what strategies they have designed for success in marketing. Budding professionals and companies can connect with industry leaders and peers for long-term networking ties. Discover innovative tips and ideas to train your employees on how your target audience wants to be engaged. To learn more, please visit https://ibn.fm/NOGfD.

• The trend toward alternative home energy already had tailwinds and just got additional support from the new climate package passed by Congress
• GeoSolar Technologies is an upstart making a name for itself with a comprehensive package to build or convert homes to zero emissions
• GST’s home technology has been installed in multiple test homes in Colorado and achieved some of the most impressive energy efficiency ratings in the industry

Every U.S. president has a legacy goal, the one thing that will always be synonymous with their name. Joe Biden has climate control high on his priority list. Sure, there are challenges, but all politics aside, there are very good reasons to be optimistic about the future and decarbonization efforts. The tech is here today and companies like GeoSolar Technologies (“GST”) are making it affordable for people to build stylish, sustainable custom homes in a way that protects the environment. For those that are still hesitant, it is time to get on board. U.S. Congress recently passing the new climate and tax package wends way to about $370 billion in alternative energy funding, which will simply add tailwinds to existing trends of global scale. Barron’s recently provided a succinct look at alternative powers that have quietly emerged to become part of our daily lives, such as U.S. wind turbines now producing more power than the entire country used in 1950 or the fact that EVs (electric vehicles) now account for 5 percent of total new car sales. It wasn’t long ago that seeing a Tesla was an anomaly. Now, it’s hard to travel more than a few minutes on a highway without seeing one after another. Denver, Colorado-based GeoSolar Technologies is pioneering innovation for people to adopt clean energy into their homes by using what Mother Earth provides. The company is a one-stop shop for an all-electric home from analysis pre-construction (or retrofit) through air quality monitoring once everything is done. Once completed, a GeoSolar home is outfitted with a state-of-the-art photovoltaic (“PV”) solar system on the roof, a new geothermal HVAC (heating, ventilation, air conditioning) system, electric car charging station, LED lighting throughout, advanced hospital-grade, whole-home air purification system (that even destroys pathogens responsible COVID-19), detoxification and insulation upgrade, and more. Using a company like GeoSolar is part of another growing movement for homeowners to take ownership of their impact towards climate change. People are more proactive than ever before and have a far greater understanding of upstream and downstream effect in addition to what is only happening on their property. In other words, the idea of repurposing material where possible is better than knowing it is being buried or burned. To heat, cool, and power a home with 100% natural energy is a matter of harnessing energy from the sun and ground without the need for fossil fuels. The idea of solar power is relatively ubiquitous anymore, with most people understanding the process of solar panels capturing the sun’s rays and converting it to power for immediate use or storage in a power bank for times the sun is not out. Geothermal is perhaps a little less understood by the mainstream, but it is growing in popularity in every place where there is even a small yard to drill and install “loops.” Geothermal is the most energy efficient means to control temperature. There are different styles and configurations, but, in short, geothermal systems operate on the fact that the ground maintains a consistent temperature around 55 degrees Fahrenheit all year. By filling the loops (underground piping) with a fluid that helps in temperature exchange, the HVAC system doesn’t have to work as hard to create hot or cool air. The benefits of the GeoSolar systems abound and are more than just aesthetics or looking at a lower utility bill. How so? Consider that children that live in homes burning natural gas are 42% more likely to develop asthma and medication spend averages $3,266 per year to treat. As far as helping the environment, a Smart Green(TM) home produces zero emissions versus a typical fossil fuel-powered house generating 5+ tons of heat trapping emissions annually. GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (“HERS”) in the industry. The Smart Green™ system can be included in the home mortgage with no money down, 100% financing, and attractive terms available. And thanks to the process of Regulation A+ offerings, interested parties have an opportunity to be an early investor in GeoSolar Technologies with investments starting at just $300. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Musicians feel financially burdened by labels and streaming platforms within the industry’s traditional structure
• Friendable’s 360-degree artist platform provides the solution to help artists produce, distribute, and market their music while retaining maximum revenue
• Since the acquisition of Artist Republik and FeaturedX, Fan Pass Live has become the only platform offering artists a full-service option – production, distribution, and marketing with support and assistance from professionals who understand the industry

Friendable (OTC: FDBL), a mobile technology company focused on its proprietary Fan Pass Live artist platform, has identified and is addressing a notable problem within the music industry for artists and record labels. With the rapid evolution of technology within the industry, music streaming platforms have become a popular distribution method, but it is not without concern, especially when looking at the revenue collected by artists for their music. In 2021, The Guardian spoke with artists, songwriters, and industry insiders about this problem, highlighting the fees collected by platforms like Spotify and Apple Music versus what the artists collect (https://ibn.fm/yarlV). On average, most musicians lose 90% of their streaming revenue to record labels, 10% to booking agents, and up to 20% of their overall income to managers. Additionally, many artists who sign with labels feel a lack of support, feel controlled, and financially burdened by strict contracts. As technology changes, it is up to artists and labels to adapt instead of keeping the outdated practices in place in an ever-changing landscape. Friendable’s solution to these industry problems is the Fan Pass Live and Artist Republik 360 artist platform, which provides next-level support for artists. The platform could solve the outdated practices the music labels provide their musicians and enhance artists’ support for production, distribution, and marketing. The 360 artist platform helps independent artists produce, distribute and market their own music, via a wide range of services that include:

• Music Distribution and Management
• Music Production Assistance
• Press Release and Instagram Promotion
• Digital Storefront Activation
• Artist Marketplace for Collaborations
• Merch, Logo, and Promotional Design Support
• Virtual Concert Booking and Ticketing Mobile Streaming Service
• Live Streaming Support
• Revenue from Fan Tips, Monthly Artist Contests, Merch, and Ticket Sales
• Access to Fan Data and Performance Analytics
• Monthly Artist Contests
• NFT Development and Metaverse Performances – Coming Soon

Artists get a unique experience when using Fan Pass Live, interacting with fans in ways other platforms do not offer – backstage and one-on-one experiences directly from the mobile device. Fans get a unique look inside the artist’s life, giving them a front-row seat before, after, and during the show. With Fan Pass Live, artists collect more of the revenue they earn through fan tips, monthly artist contests, merchandise sales, and ticket sales. These earnings go back to the artist instead of in the hands of a middleman or record label, changing the industry’s dynamic – in favor of the artist over the managing entity. Artists are also getting the support they need from staff versed in the music industry, giving them feedback and guidance on both professional and personal levels. Friendable’s flagship offering, Fan Pass Live, was released in July 2020. In January 2022, the company completed its acquisition of Artist Republik and FeaturedX, creating the 360-degree platform for artists to receive the support and resources necessary to pursue independent music careers. Since the acquisition, the platform has seen an increase in site metrics, including 4.5k average unique monthly visitors, four-minute average session duration, 17% monthly conversion rate average, and 1k monthly social referral average. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• EverGen Infrastructure recently acquired a majority stake in an Alberta-based potato farming operation, focused around capturing methane emissions from organic waste, and upgrading it to Renewable Natural Gas to sell to utilities
• The company has recently stated a goal to expand to 20 production sites within 5 years as they seek to capitalize on the Canadian electric grid’s move towards securing renewable energy feedstocks
• In recent years, a number of Canadian provinces have introduced RNG mandates for their energy supplies
• That move will soon be mimicked in the United States, with the $430bn climate bill set to be signed into law

Nestled in the foothills of the Canadian Rocky Mountains, the Perry family’s potato farming operations have supplied the likes of Frito-Lay and McCain Foods Ltd for over a generation. In recent years however, the Alberta-based operation has sought to capitalize on their agrarian operations in a manner that may not have been envisioned by its original founders – the production of renewable natural gas (“RNG”). GrowTEC, the Perry family’s power generation operation, seeks to capture the methane produced by over 15,000 tonnes of decomposing potatoes and other waste annually, using the generated electricity to power their farming operations whilst selling any excess power to the provincial grid. In July, the Perrys agreed to sell two-thirds of their budding biogas business to EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF), a British-Columbia based natural gas operator, for $2.1 million. In return, EverGen will fund the investments needed to upgrade the company’s gas production, enabling it to be injected into the pipeline network under a 20-year contact with FortisBC, British Columbia’s main gas utility. Since 2010, the global movement to replace coal with gas for power generation has prevented over 500 million tonnes of carbon dioxide from being released into the atmosphere, the carbon equivalent of upwards of 200 million internal combustion engine vehicles being replaced by electric vehicles. Nonetheless, methane production, which emanates from decomposing organic waste in landfills, food waste and wastewater and is said to be at least 25 times more potent as a climate-warming gas relative to carbon dioxide, has gone largely unchecked. The Canadian Biogas Association has recently revealed that the production of biogas and renewable natural gas could halve the collective potential to cut the nation’s methane emissions – a primary feedstock for biogas and RNG, by as much as half as of 2030. The movement has gained further impetus with various Canadian provinces introducing mandates to boost RNG use in recent years; in 2019, Quebec states that its gas grid would blend a minimum of 1-percent RNG into its feedstock mix, a figure set to rise to as much as 10 percent by 2030. EverGen Infrastructure has sought to capitalize on the move towards increased RNG production, with a publicly stated goal to own over 20 facilities across the country within five years – an aim which has underpinned the company’s purchase of a majority stake in the Perry family’s GrowTEC operation as well as several others of the kind. “We are a renewable natural gas energy company. We’re a developer, owner and operator of projects that take organic waste and convert that organic waste into renewable energy in the form of renewable natural gas (‘RNG’),” stated Chase Edgelow, Co-Founder and CEO of EverGen Infrastructure Cop. “[Canadian utilities, like FortisBC] offer 20-year contracted offtakes to companies like ours to supply them with green energy, which provides a certainty for our business. Our business is then going out and building facilities that will take organic waste and convert it into RNG.” Moreover, the movement towards cleaner fuel sources has not been confined to Canada alone. In early September 2022, the United States Government is set to sign into law a $430 billion bill, widely hailed as the biggest climate package in U.S. history, with an objective to cut domestic greenhouse gas emissions. In addition to boosting production of traditional renewable energy sources such as wind, solar, and hydro—electric power, the bill will also seek to boost production of the likes of hydrogen and renewable natural gas, an aim recently lauded by Mr. Edgelow. “If you look back at the benefits of bringing in other sources of energy 20 years ago, there wasn’t one silver bullet for the electrical grid to be as renewable as it is today, with wind, solar and hydro,” he said. I think renewable natural gas can hold its own, and at the same time solve a massive waste problem and emissions problem from waste.” For more information, visit the company’s website at www.EvergenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF